1. Signaling Pathways
  2. GPCR/G Protein
  3. Prostaglandin Receptor

Prostaglandin Receptor

Prostaglandin receptor, a sub-family of cell surface seven-transmembrane receptors, are the G-protein-coupled receptors. There are currently ten known prostaglandin receptors on various cell types. Prostaglandins bind to a subfamily of cell surface seven-transmembrane receptors, G-protein-coupled receptors. These receptors are named: DP1-2-DP1, DP2 receptors, EP1-4-EP1, EP2, EP3, EP4 receptors, FP-FP, IP1-2-IP1, IP2 receptors, TP-TP receptor. The prostaglandins are a group of hormone-like lipid compounds that are derived enzymatically from fatty acids and have important functions in the animalbody. There are currently ten known prostaglandin receptors on various cell types.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-10414
    MK-2894 sodium salt
    Antagonist 98.94%
    MK-2894 sodium salt is a potent, selective, orally active and high affinity (Ki=0.56 nM) full antagonist against E prostanoid receptor 4 (EP4 receptor) (IC50=2.5 nM). MK-2894 sodium salt possesses potent anti-inflammatory activity in animal models of pain/inflammation and can be used for the research of arthritis.
    MK-2894 sodium salt
  • HY-114810
    Prostaglandin F2α serinol amide
    Agonist 99.41%
    Prostaglandin F2α serinol amide is a serinolamide G protein-coupled receptor that increases calcium levels in human non-small cell lung cancer cells. Prostaglandin F2α is also a luteinizing hormone in sheep and may be a nociceptive mediator in the spinal cord.
    Prostaglandin F2α serinol amide
  • HY-120980
    Thromboxane B1
    Thromboxane B1 (TXB1) is one of thromboxane B (TXB) family members. Thromboxane is a member of the family of lipids known as eicosanoids. Thromboxane is named for its role in blood clot formation (thrombosis).
    Thromboxane B1
  • HY-101438A
    Darbufelone mesylate
    Inhibitor 99.65%
    Darbufelone mesylate (CI-1004 mesylate) is a dual inhibitor of cellular PGF and LTB4 production. Darbufelone potently inhibits PGHS-2 (IC50 = 0.19 μM) but is much less potent with PGHS-1 (IC50= 20 μM).
    Darbufelone mesylate
  • HY-101988S1
    Prostaglandin D2-d9
    Activator 99.0%
    Prostaglandin D2-d9 is the deuterium labeled Prostaglandin D2. Prostaglandin D2 (PGD2) is one of the major PGs actively produced in the brain of various mammals. Prostaglandin D2 is one of the most potent endogenous sleep promoting substances. PGD2 plays a protective role by suppressing inflammation.
    Prostaglandin D2-d<sub>9</sub>
  • HY-14870S1
    Selexipag-d7
    Agonist 98.44%
    Selexipag-d7 is the deuterium labeled Selexipag. Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (PGI2) receptor (IP receptor).
    Selexipag-d<sub>7</sub>
  • HY-137119
    (±)5-iPF2α-VI
    Control 99.0%
    (±)5-iPF2α-VI (5-iso Prostaglandin F2α-VI) is the racemate of 5-iPF2α-VI. 5-iPF2α-VI is a regioisomeric isoprostane formed from arachidonic acid (AA) and is a biomarker of oxidative stress.
    (±)5-iPF2α-VI
  • HY-121314
    Cloprostenol
    99.86%
    Cloprostenol is a prostaglandin F2α (PGF2α (HY-12956)) analogue. Cloprostenol can induce luteolysis. Cloprostenol can be used for open-cervix pyometra research.
    Cloprostenol
  • HY-108563
    SC 51089
    Antagonist
    SC 51089 is a selective antagonist of prostaglandin E2 EP1 receptor, with Kis of 1.3, 11.2, 17.5, and 61.1 μM for EP1, TP, EP3, and FP receptors, respectively. SC 51089 exhibits neuroprotective activity.
    SC 51089
  • HY-107795R
    Benorilate (Standard)
    Inhibitor
    Benorilate (Standard) is the analytical standard of Benorilate. This product is intended for research and analytical applications. Benorylate (Salipran) is the esterification product of paracetamol and acetylsalicylic acid. Benorylate has anti-inflammatory, analgesic and antipyretic properties. Benorylate could also inhibit prostaglandin (PG) synthesis.
    Benorilate (Standard)
  • HY-13569AR
    Beraprost sodium (Standard)
    Beraprost (sodium) (Standard) is the analytical standard of Beraprost (sodium). This product is intended for research and analytical applications. Beraprost sodium, a prostacyclin analog, is a stable and orally active proagent of PGI2. Beraprost sodium is a potent vasodilator, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation. Beraprost (sodium) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Beraprost sodium (Standard)
  • HY-W009706
    Alclofenac
    Inhibitor 99.44%
    Alclofenac (Allopydin) is a non-steroidal anti-inflammatory agent (NSAID). Alclofenac is a prostaglandin H2 synthase inhibitor. Alclofenac can be used for rheumatoid arthritis, degenerative joint disease and ankylosing spondylitis research.
    Alclofenac
  • HY-12182
    ONO-8711
    Antagonist
    ONO-8711 is a potent and selective competitive antagonist of EP1 receptor (Ki = 0.6 and 1.7 nM for human and mouse EP1 respectively). ONO-8711 effectively reduces tumor incidence and multiplicity in mouse models of colon, breast, and oral cancer.
    ONO-8711
  • HY-Z7721
    (Rac)-Beraprost sodium
    Inhibitor 99.0%
    (Rac)-Beraprost ((Rac)-ML 1129) sodium is a racemic isomer of Beraprost sodium (HY-13569A). Beraprost sodium is an orally active prostacyclin analog that inhibits the release of Ca2+ from intracellular storage sites by binding to prostacyclin membrane receptors (Prostaglandin Receptor), leading to relaxation of smooth muscle cells and vasodilation. Beraprost sodium has vasodilatory, antiplatelet, and cytoprotective effects, making it promising for research in the field of cardiovascular diseases, such as thromboangiitis obliterans and atherosclerosis.
    (Rac)-Beraprost sodium
  • HY-135163
    trans-Latanoprost
    Control 98.35%
    trans-Latanoprost (5,6-trans-Latanoprost) is the trans isomer of Latanoprost (HY-B0577). trans-Latanoprost is promising for research of glaucoma and high eye pressure.
    trans-Latanoprost
  • HY-B0195A
    Tranilast sodium
    Inhibitor
    Tranilast sodium (MK-341 sodium) acts as an anti-atopic agent. Tranilast suppresses production of prostaglandin D2 (PGD2, IC50= 0.1 mM). Tranilast sodium exhibits anti-inflammatory and immunomodulatory effects. Tranilast sodium antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells.
    Tranilast sodium
  • HY-A0096S
    Iloprost-d4
    Agonist
    Iloprost-d4 (Ciloprost-d4) is the deuterium labeled Iloprost. Iloprost (ZK 36374) is a synthetic analogue of prostacyclin PGI2.
    Iloprost-d<sub>4</sub>
  • HY-137308
    15(R)-Prostaglandin D2
    99.9%
    15(R)-Prostaglandin D2 is a potential prostatic hormone DP(2) receptor (Prostaglandin Receptor) agonist with anti-inflammatory activity. 15(R)-Prostaglandin D2 increases actin polymerization in human eosinophils and increases cAMP levels in platelets.
    15(R)-Prostaglandin D2
  • HY-B0774R
    Seratrodast (Standard)
    Antagonist
    Seratrodast (Standard) is the analytical standard of Seratrodast. This product is intended for research and analytical applications. Seratrodast (AA 2414), an orally active antiasthmatic agent, is a thromboxane A2 receptor (TP) antagonist and ferroptosis inhibitor. Seratrodast reduces lipid ROS production, modulates the systemic xc-/GSH/GPX4 axis, and inhibits JNK phosphorylation and p53 expression. Seratrodast exhibits anti-asthmatic and anti-epileptic activity.
    Seratrodast (Standard)
  • HY-158332
    Sulotroban
    Antagonist 99.29%
    Sulotroban (SKF-95587; BM-13177) is a selective antagonist for thromboxane A2 receptor (TXA2 Receptor). Sulotroban exhibits inhibitory activity against carbocyclic thromboxane A2- and endoperoxide-induced vasoconstrictor. Sulotroban inhibits platelets aggregation.
    Sulotroban
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.